Full TitleA Phase 2 Trial of ZW25 in HER2 Overexpressed Advanced Endometrial Cancers and Carcinosarcomas (ZW25-IST-2)
The purpose of this study is to assess the safety and effectiveness of the investigational drug ZW25 in women with advanced endometrial cancer or carcinosarcoma that has come back or continues to grow despite prior treatment and has high levels of a protein called HER2.
As a “bispecific antibody,” ZW25 is designed to attach to two different parts of the HER2 protein on the surface of cancer cells. Researchers believe that attaching ZW25 to the HER2 protein can remove this protein from cancer cells, which could boost the immune system’s ability to kill these cells and slow the growth of cancer. ZW25 is given intravenously (by vein).
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have advanced endometrial cancer or carcinosarcoma that came back or continues to grow despite one or two prior regimens of chemotherapy.
- Patients should recover from the serious side effects of previous treatments before entering the study.
- Patients must be physically well enough that they are fully ambulatory, capable of all self-care, and capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
- This study is for women age 18 and older.
For more information about this study and to inquire about eligibility, please contact Dr. Vicky Makker at 646-888-4224.